orp-101
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04129619)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Kappa opioid receptorAGONIST
OPRK1 agonist
- Kappa opioid receptorANTAGONIST
Kappa opioid receptor antagonist
- Mu opioid receptorPARTIAL AGONIST
Mu opioid receptor partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5- Mol. weight
- 961.34 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594402 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04129619 | Phase 2 | Nov 30, 2019 | OrphoMed, Inc., PPD |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OrphoMed, Inc. | For profit | 1 | 1 | 1 | 2019 |
| PPD | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1